The team at Saint Luke’s Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient. It’s what Saint Luke’s calls precision medicine: the right treatment for the right patient at the right time.

We offer the region’s only precision oncology program for advanced cancers that’s staffed by clinical oncologists with expertise in genomic sequencing and computational biology. With our clinical trial agreement with the internationally recognized Washington University School of Medicine, we can offer more than 200 National Cancer Institute-sponsored clinical trials and industry-led studies to Saint Luke’s Cancer Institute patients.

Personalized Cancer Treatment

Saint Luke’s Cancer Institute offers options for patients at every stage in their cancer journey:

Second Opinions

When it comes to potentially life-changing or lifesaving treatments, patients and their families often seek a second opinion. Second opinions can provide:

  • Confirmation of a diagnosis
  • More details about type of cancer and stage, which affect treatment options
  • Perspective from subspecialized oncologists

If you started your cancer journey at another facility, the experts at Saint Luke’s Cancer Institute are available to review your records and provide a thoughtful second opinion, including personalized treatment options available at Saint Luke’s.

Classes and Events

  • Gilda’s Club Kansas City
  • Look Good Feel Better
  • Breast Cancer Support Groups
  • Nutrition for Cancer Survivorship 
  • Dr. Jeffrey Wieman Cancer Prevention Lecture Series 

View all classes and events.

Clinical Trials Available at Saint Luke's

For more information about clinical trials at Saint Luke's Cancer Institute, call 816-932-2677.

Advanced Solid Tumor
  • EAY131 Molecular Analysis for Therapy Choice (MATCH)
    Learn more
  • A Prospective Registry Study to Evaluate the Efficacy of Personalized Medicine on Advanced Solid Tumors
Breast Cancer
  • SGNTUC-025-A single arm, open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locally-advanced or metastatic Her2+ breast cancer
    Learn more
  • Seattle Genetics SGNTUC-016 Seattle Genetics Phase 3 clinical trial of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer (SGNTUC-016)
    Learn more
  • Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
    Learn more
  • A021703 Randomized double-blind Phase III trial of Vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer (SOLARIS)
    Learn more
  • A221805-Duloxetine to prevent oxaliplatin-induced chemo-induced peripheral neuropathy: randomized double blind placebo-controlled phase II to Phase III study
    Learn more
  • BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
    Learn more
GI (Pancreatic)
  • EA2186 A randomized phase II study of gemcitabine and nab-paclitaxel copared with 5-FU, leucovorin, and liposomal irinotecan in older patients with treatment naive metastatic pancreatic cancer (GIANT)
    Learn more
GU (Urothelial)
  • A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer (CheckMate901)
    Learn more
Lung Cancer
  • Pacific 4: Phase III, Randomized, Placebo-controlled, double-blind, multi-center, international study of durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with unresected Stage I/II, lymph node-negative NSCLC
    Learn more
  • Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
    Learn more
  • A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
    Learn more
  • Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
    Learn more
  • Lung Map: Master Protocol for Treatment of Non-Small Cell Lung Cancer
    Learn more


Saint Luke's Cancer Institute

Saint Luke's News

Nov. 27, 2023
KCUR: Many Adults Are Dissatisfied with Life. Kansas City-Area Experts Say Gratitude and Connection Help
KCUR talked to Kadie Harry about how individualized approaches can lead to more fulfilled lives.
Oct. 30, 2023
KCTV: Exploring Breast Cancer Screening Options
More women are being diagnosed with breast cancer under the age of 45, also known as early onset breast cancer.
Oct. 27, 2023
Health News You Can Use: Innovative Treatments & Clinical Trials for Breast Cancer
Dr. Tim Pluard, medical director of Saint Luke’s Koontz Center for Advanced Breast Cancer and of Saint Luke’s Cancer Institute, talks about innovative treatment options for breast cancer and clinical trials offered at Saint Luke’s.